HER2 Mutation Detection Kit

HER2 Mutation Detection Kit

Qualitative detection of Detection of five mutations in HER2 gene

HER2 mutations in exons 19~20, have been identified in approximately 2~4%of non–small-cell lung cancers (NSCLC). HER2 mutations appear to be found more commonly in never smokers with adenocarcinoma histology. The most common mutation is an in-frame insertion in exon 20. These insertions cause activation of downstream HER2-pathway components such as AKT and MEK. Drugs targeting HER2 include afatinib, traztuzumab, lapatinib, pertuzumab, neratinib and T-DMI. A recent study by Mazieres[1] highlighted the importance of screening for HER2 mutations in NSCLC and suggests that HER2-positive patients may be responsive to HER2-targeted therapy.

Technological Principles

The kit uses novel, proprietary primers and probes in a real-time PCR assay to detect 13 HER2 mutations in human genomic DNA. The mutant HER2 gene is amplified by the specific primers, and detected by the fluorescent probes.